Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CV industry veteran succeeds Howlett as Lombard CEO

This article was originally published in Clinica

Executive Summary

John Rush, a medical device industry veteran with particular experience in the cardiovascular sector, has succeeded Brian Howlett as CEO of UK stent graft developer Lombard Medical Technologies. Mr Rush, a US national, spent 10 years at SciMed Life Systems (which was bought by Boston Scientific in 1994) in various senior sales and marketing and management roles. He has been president and CEO of several small-cap companies, most recently at North American Scientific (NAS), where he led the firm's reorganisation and financial recovery. Mr Rush is expected to take Lombard through the next growth phase, as it expands commercialisation in Europe and secures FDA approval for its flagship Aorfix device. His predecessor, Mr Howlett, will be retiring after nearly four years at Lombard's helm, but will remain with the London firm as executive director until the end of March 2010 to oversee the transition.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT044472

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel